human | Q5 |
P6178 | Dimensions author ID | 01013015150.44 |
P496 | ORCID iD | 0000-0002-7314-8204 |
P69 | educated at | University of London | Q170027 |
P108 | employer | St. Mary's Hospital | Q3495342 |
St Bartholomew's Hospital | Q164946 | ||
University of Birmingham | Q223429 | ||
Hammersmith Hospital | Q5645747 | ||
Royal Marsden Hospital | Q50575536 | ||
West Suffolk Hospital | Q50804992 | ||
P734 | family name | James | Q12188082 |
James | Q12188082 | ||
James | Q12188082 | ||
P735 | given name | Nicholas | Q42771 |
Nicholas | Q42771 | ||
P106 | occupation | researcher | Q1650915 |
Q92853473 | Abiraterone in "High-" and "Low-risk" Metastatic Hormone-sensitive Prostate Cancer |
Q64933248 | Changing platforms without stopping the train: experiences of data management and data management systems when adapting platform protocols by adding and closing comparisons. |
Q41760505 | Defining bowel dose volume constraints for bladder radiotherapy treatment planning |
Q91939947 | Health-related quality of life around the time of diagnosis in patients with bladder cancer |
Q38372741 | Integrated Care in Prostate Cancer (ICARE-P): Nonrandomized Controlled Feasibility Study of Online Holistic Needs Assessment, Linking the Patient and the Health Care Team |
Q91311579 | Prognostic and predictive models in hormone-sensitive prostate cancer |
Q91940769 | Targeted deep sequencing of urothelial bladder cancers and associated urinary DNA: a 23-gene panel with utility for non-invasive diagnosis and risk stratification |
Q64897640 | This is a platform alteration: a trial management perspective on the operational aspects of adaptive and platform and umbrella protocols. |
Q49503108 | Transdermal Oestradiol as a method of androgen suppression for Prostate Cancer within the STAMPEDE Trial Platform |
Search more.